Ken Cai1, Amy Fuller2, Owen Hensey3, David Grossberg4, Robin Christensen5, Beverley Shea6, Jasvinder A Singh7, Abhishek Abhishek2, Sara Tedeschi8, Nicola Dalbeth9. 1. Bone and Joint Research Group, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, New Zealand. Electronic address: k.cai@auckland.ac.nz. 2. Academic Rheumatology, University of Nottingham, Nottingham, UK; Nottingham NIHR-BRC, Nottingham, UK. 3. The Central Remedial Clinic, Dublin, Ireland. 4. Holy Cross Hospital, Silver Spring, MD, USA; Suburban Hospital, Bethesda, MD, USA. 5. Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen & Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark. 6. Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada. 7. Medicine Service, VA Medical Center, Birmingham, AL, USA; Department of Medicine at the School of Medicine, University of Alabama at Birmingham (UAB), Birmingham, AL, USA; Department of Epidemiology, at the UAB School of Public Health, Birmingham, AL, USA. 8. Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, USA. 9. Bone and Joint Research Group, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, New Zealand.
Abstract
INTRODUCTION: Although calcium pyrophosphate deposition (CPPD) is common, there are no validated outcome domains and/or measurements for CPPD studies. The aim of this work was to identify domains that have been reported in prior clinical studies in CPPD, to inform the development of a core set of domains for CPPD studies. METHODS: We performed a scoping literature review for clinical studies in CPPD, searching in Medline (via PubMed), EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) databases; published from January 1, 1946 to January 7, 2020. All reported outcomes and study design data were extracted and mapped to the core areas and domains as defined by the OMERACT Filter 2.1.The protocol was registered on PROSPERO (CRD: 42019137075; 09-07-2019). FINDINGS: There were 112 papers identified, comprising of 109 observational studies and three randomized controlled trials. Most studies reported clinical presentations of OA with CPPD or acute CPP crystal arthritis. Outcomes that mapped to 22 domains were identified; the most frequently reported measures mapped to the following domains/sub-domains: imaging (joint damage on imaging tests - 59 studies; joint calcification on imaging tests - 28 studies), joint pain (26 studies), response to treatment (23 studies), side effects of treatment (15 studies), inflammation in the joint fluid or blood (ESR or C-reactive protein - 12 studies; synovial fluid markers - 4 studies; other blood markers - 2 studies), overall function (14 studies), joint swelling (12 studies) and range of joint movement (10 studies). Very few studies mapped to domains related to life impact, societal/resource use or longevity. CONCLUSION: There is substantial variability in outcomes reported in CPPD studies. Outcomes that map to imaging manifestations, joint pain and response to treatment domains are most often reported.
INTRODUCTION: Although calcium pyrophosphate deposition (CPPD) is common, there are no validated outcome domains and/or measurements for CPPD studies. The aim of this work was to identify domains that have been reported in prior clinical studies in CPPD, to inform the development of a core set of domains for CPPD studies. METHODS: We performed a scoping literature review for clinical studies in CPPD, searching in Medline (via PubMed), EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) databases; published from January 1, 1946 to January 7, 2020. All reported outcomes and study design data were extracted and mapped to the core areas and domains as defined by the OMERACT Filter 2.1.The protocol was registered on PROSPERO (CRD: 42019137075; 09-07-2019). FINDINGS: There were 112 papers identified, comprising of 109 observational studies and three randomized controlled trials. Most studies reported clinical presentations of OA with CPPD or acute CPP crystal arthritis. Outcomes that mapped to 22 domains were identified; the most frequently reported measures mapped to the following domains/sub-domains: imaging (joint damage on imaging tests - 59 studies; joint calcification on imaging tests - 28 studies), joint pain (26 studies), response to treatment (23 studies), side effects of treatment (15 studies), inflammation in the joint fluid or blood (ESR or C-reactive protein - 12 studies; synovial fluid markers - 4 studies; other blood markers - 2 studies), overall function (14 studies), joint swelling (12 studies) and range of joint movement (10 studies). Very few studies mapped to domains related to life impact, societal/resource use or longevity. CONCLUSION: There is substantial variability in outcomes reported in CPPD studies. Outcomes that map to imaging manifestations, joint pain and response to treatment domains are most often reported.
Authors: Sara K Tedeschi; Tristan Pascart; Augustin Latourte; Cattleya Godsave; Burak Kundakci; Raymond P Naden; William J Taylor; Nicola Dalbeth; Tuhina Neogi; Fernando Perez-Ruiz; Ann Rosenthal; Fabio Becce; Eliseo Pascual; Mariano Andres; Thomas Bardin; Michael Doherty; Hang-Korng Ea; Georgios Filippou; John FitzGerald; Marwin Guitierrez; Annamaria Iagnocco; Tim L Jansen; Minna J Kohler; Frédéric Lioté; Mark Matza; Geraldine M McCarthy; Roberta Ramonda; Anthony M Reginato; Pascal Richette; Jasvinder A Singh; Francisca Sivera; Alexander So; Lisa K Stamp; Janeth Yinh; Chio Yokose; Robert Terkeltaub; Hyon Choi; Abhishek Abhishek Journal: Arthritis Care Res (Hoboken) Date: 2022-06-30 Impact factor: 5.178
Authors: Ken Cai; Amy Fuller; Yiling Zhang; Owen Hensey; David Grossberg; Robin Christensen; Beverley Shea; Jasvinder A Singh; Geraldine M McCarthy; Ann K Rosenthal; Georgios Filippou; William J Taylor; Cesar Diaz-Torne; Lisa K Stamp; N Lawrence Edwards; Tristan Pascart; Fabio Becce; Sabrina M Nielsen; Peter Tugwell; Dorcas Beaton; Abhishek Abhishek; Sara K Tedeschi; Nicola Dalbeth Journal: Semin Arthritis Rheum Date: 2021-06-14 Impact factor: 5.431